Patient behavior has always had an influence on clinical trials - so how do we contend with missing and/or irregular data now that it is feeding AI models? And how do providers continue to work with patients to optimize and grow data pools?
This is the third and final part of a discussion focused upon data bias, accuracy, access and the future of AI in drug development.

Host 
⁠⁠Lori Ellis⁠⁠, Head of Insights, BioSpace  

Guests 
⁠⁠Paul Agapow⁠⁠, Director of Innovation, Data Science and Strategy, GlaxoSmithKline⁠⁠⁠
⁠Mike King⁠⁠, Senior Director of Product and Strategy, IQVIA 
⁠⁠Nindhana Paranthaman⁠⁠, Executive Medical Director, Exelixis 
⁠⁠Moritz von Stosch⁠⁠, Chief Information Officer, DataHow